Study Summary
This trial will evaluate the safety and efficacy of ABBV-637 in participants with solid tumors. ABBV-637 will be given alone or in combination with docetaxel/osimertinib in 28-day cycles.
- Malignant Neoplasms
- Non-Small Cell Lung Carcinoma (NSCLC)
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 8 Secondary · Reporting Duration: Up to approximately 3 years
Trial Safety
Safety Progress
Trial Design
5 Treatment Groups
Part 2a: ABBV-637 + Docetaxel
1 of 5
Part 3a: ABBV-637 + Osimertinib
1 of 5
Part 2b: ABBV-637 + Docetaxel
1 of 5
Part 1: ABBV-637 Monotherapy
1 of 5
Part 3b: ABBV-637 + Osimertinib
1 of 5
Experimental Treatment
109 Total Participants · 5 Treatment Groups
Primary Treatment: ABBV-637 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 17th, 2021
Last Reviewed: November 24th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.